Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
ZEVRA THERAPEUTICS, INC. incurred credit facility of $100.0 million with HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP at 3-Month Term SOFR plus 7.00% per annum maturing fifth anniversary of the Closing Date.
- Instrument
- credit facility
- Principal
- $100.0 million
- Counterparty
- HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP
- Rate
- 3-Month Term SOFR plus 7.00% per annum
- Maturity
- fifth anniversary of the Closing Date
- Event
- incurrence
Exact text from the filing
the Lenders provided a senior secured loan facility to the Company in the aggregate principal amount of $100.0 million (the “Debt Financing”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ZEVRA THERAPEUTICS, INC. entered into Credit Agreement with HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP as lenders valued at $100.0 million (effective 2024-04-05).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP as lenders
- Value
- $100.0 million
- Effective
- 2024-04-05
Exact text from the filing
On April 5, 2024 (the "Closing Date"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or the "Company"), as the borrower, entered into a credit agreement (the "Credit Agreement") among the Company, Acer Therapeutics, Inc., a Delaware corporation ("Acer"), Epyon Therapeutics, Inc., a Delaware corporation ("Epyon"), and Zevra Denmark A/S, a public limited liability company organized under the laws of Denmark (together with Acer and Epyon, collectively, the "Guarantors"), HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP as lenders (collectively, the "Lenders"), and Alter Domus (US) LLC, as administrative agent (the "Administrative Agent").
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ZEVRA THERAPEUTICS, INC. terminated Note Purchase Agreement with Nantahala Capital Management, LLC (effective 2024-04-04).
- Action
- termination
- Agreement
- notes offering
- Counterparty
- Nantahala Capital Management, LLC
- Effective
- 2024-04-04
Exact text from the filing
On April 4, 2024, in connection with the Debt Financing, the Company delivered to Nantahala Capital Management, LLC ("NCM"), certain of its affiliates and certain other parties (collectively with NCM, "Nantahala") a payoff letter in connection with its repayment of amounts outstanding under the Note Purchase Agreement with Nantahala (the "Note Purchase Agreement"), dated August 30, 2023.
View on SEC.gov